NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Novo Nordisk A/S (CO: NOVO-B)

 
NOVO-B Technical Analysis
5
As on 5th Aug 2025 NOVO-B SHARE Price closed @ 305.90 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 849.97 & Strong Sell for SHORT-TERM with Stoploss of 873.20 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

NOVO-BSHARE Price

Open 313.30 Change Price %
High 314.85 1 Day -7.10 -2.27
Low 305.45 1 Week -146.20 -32.34
Close 305.90 1 Month -147.15 -32.48
Volume 10425489 1 Year -541.00 -63.88
52 Week High 1028.00 | 52 Week Low 308.80
 
CO Denmark Most Active Stocks
NOVO-B 305.90 -2.27%
SAS 0.01 0.00%
CONFRZ 0.02 0.00%
VWS 117.95 -0.42%
GREENH 0.41 -6.82%
ALMB 18.13 -0.17%
ASTRLS 1.15 8.49%
BIF 0.33 -2.94%
BLVIS-A 0.40 -18.37%
DANSKE 257.50 -1.00%
 
CO Denmark Top Gainers Stocks
HYDRCT 0.60 46.34%
HYPE 3.66 22.00%
DKIEEU 249.00 15.81%
SAME 1.45 10.69%
SAME 1.45 10.69%
VIRO 10.50 10.53%
BOOZT-DKK 64.10 9.85%
ASTRLS 1.15 8.49%
EGNETY 179.00 8.48%
MDUNDO 5.45 6.86%
 
CO Denmark Top Losers Stocks
VALUER 0.25 -21.88%
BLVIS-A 0.40 -18.37%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
ACT 0.72 -12.20%
 
 
NOVO-B
Daily Charts
NOVO-B
Intraday Charts
Whats New @
Bazaartrend
NOVO-B
Free Analysis
 
NOVO-B Important Levels Intraday
RESISTANCE324.01
RESISTANCE318.20
RESISTANCE314.61
RESISTANCE311.02
SUPPORT300.78
SUPPORT297.19
SUPPORT293.60
SUPPORT287.79
 
NOVO-B Forecast August 2025
4th UP Forecast547.74
3rd UP Forecast470.18
2nd UP Forecast422.24
1st UP Forecast374.3
1st DOWN Forecast237.5
2nd DOWN Forecast189.56
3rd DOWN Forecast141.62
4th DOWN Forecast64.06
 
NOVO-B Weekly Forecast
4th UP Forecast393.58
3rd UP Forecast365.46
2nd UP Forecast348.08
1st UP Forecast330.70
1st DOWN Forecast281.10
2nd DOWN Forecast263.72
3rd DOWN Forecast246.34
4th DOWN Forecast218.22
 
NOVO-B Forecast2025
4th UP Forecast1727.45
3rd UP Forecast1271.55
2nd UP Forecast989.75
1st UP Forecast707.95
1st DOWN Forecast-96.15
2nd DOWN Forecast-377.95
3rd DOWN Forecast-659.75
4th DOWN Forecast-1115.65
 
 
NOVO-B Other Details
Segment EQ
Market Capital 1565371138048.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
NOVO-B Address
NOVO-B
 
NOVO-B Latest News
 
Your Comments and Response on Novo Nordisk A/S
 
NOVO-B Business Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Allé 1, Bagsvaerd, Denmark, 2880
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service